chromium picolinate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4511 14639-25-9

Description:

MoleculeDescription

Synonyms:

  • chromium picolinate
  • chromium tripicolinate
iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206
  • Molecular weight: 418.31
  • Formula: C18H12CrN3O6
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral venous thrombosis 160.89 48.09 24 281 1847 50602972
Thalamic infarction 106.11 48.09 14 291 433 50604386
Slow response to stimuli 58.18 48.09 9 296 860 50603959

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral venous thrombosis 157.85 43.50 24 313 2417 64495978
Thalamic infarction 95.32 43.50 14 323 1098 64497297
Slow response to stimuli 54.16 43.50 9 328 1556 64496839

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D002614 Chelating Agents
MeSH PA D007502 Iron Chelating Agents
MeSH PA D064449 Sequestering Agents
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:50733 Dietary Supplement
CHEBI has role CHEBI:74518 anti-obestic agents
CHEBI has role CHEBI:176497 geroprotectors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Poisoning by digitalis glycoside contraindication 12876009
Constipation contraindication 14760008 DOID:2089
Hyperphosphatemia contraindication 20165001 DOID:0050459
Hypervitaminosis D contraindication 27712000 DOID:9971
Sarcoidosis contraindication 31541009 DOID:11335
Hypercalcemia contraindication 66931009 DOID:12678
Hypercalciuria contraindication 71938000
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Arteriosclerosis obliterans contraindication 361133006 DOID:5160




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4020557 VUID
N0000148263 NUI
4020557 VANDF
CHEBI:50369 CHEBI
CHEMBL4297201 ChEMBL_ID
CHEMBL3185022 ChEMBL_ID
C030614 MESH_SUPPLEMENTAL_RECORD_UI
C079689 MESH_SUPPLEMENTAL_RECORD_UI
DB11255 DRUGBANK_ID
S71T8B8Z6P UNII
151932 PUBCHEM_CID
59308 RXNORM
38299 MMSL
4442 MMSL
6684 MMSL
d04142 MMSL
005140 NDDF
C0163657 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vita-Rx Diabetic Vitamin HUMAN PRESCRIPTION DRUG LABEL 14 65121-301 CAPSULE, GELATIN COATED 0.47 mg ORAL unapproved drug other 5 sections
Vita-Rx Diabetic Vitamin HUMAN PRESCRIPTION DRUG LABEL 14 69677-050 CAPSULE, GELATIN COATED 0.47 mg ORAL unapproved drug other 5 sections